AR040971A1 - Compuestos pirimido que tienen actividad antiproliferativa - Google Patents
Compuestos pirimido que tienen actividad antiproliferativaInfo
- Publication number
- AR040971A1 AR040971A1 ARP030102914A ARP030102914A AR040971A1 AR 040971 A1 AR040971 A1 AR 040971A1 AR P030102914 A ARP030102914 A AR P030102914A AR P030102914 A ARP030102914 A AR P030102914A AR 040971 A1 AR040971 A1 AR 040971A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkyl
- independently selected
- nr5r6
- atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000037841 lung tumor Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se presentan compuestos que son inhibidores selectivos de ambas KDR y FGFR quinasas y son selectivas contra LCK. Estos compuestos y sus sales farmacéuticamente aceptables son agentes antiproliferativos útiles en el tratamiento o control de tumores sólidos, en particular tumores de mama, colon, pulmón y próstata. También se revelan composiciones farmacéuticas que contienen estos compuestos y un proceso para su preparación. Reivindicación 1: Un compuesto de fórmula (1) o sales farmacéuticamente aceptables del mismo, en donde R1 se selecciona del grupo, -H, -COR4, y -COOCHR5OCOR4; R2 y R3 se seleccionan independientemente de -H, y -OR5; R4 se selecciona del grupo -C1-6 alquilo; C1-6 alquilo sustituido por hasta 4 grupos seleccionados independientemente de -NR5R6, -SR5, -OR5, arilo, arilo sustituido por hasta 2 grupos seleccionados independientemente de -OR5 y C1-4 alquilo, y heteroarilo, y heterociclo; R5 y R6 se seleccionan independientemente de -H y C1-5 alquilo, o, alternativamente, -NR5R6 puede formar un anillo que tiene de 3 a 7 átomos, dicho anillo que incluye opcionalmente uno o más átomos de O o N adicionales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40351902P | 2002-08-14 | 2002-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040971A1 true AR040971A1 (es) | 2005-04-27 |
Family
ID=31946709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102914A AR040971A1 (es) | 2002-08-14 | 2003-08-12 | Compuestos pirimido que tienen actividad antiproliferativa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7084270B2 (es) |
| EP (1) | EP1556384B1 (es) |
| JP (1) | JP2005538141A (es) |
| KR (1) | KR20070087687A (es) |
| CN (1) | CN1323080C (es) |
| AR (1) | AR040971A1 (es) |
| AT (1) | ATE386743T1 (es) |
| AU (1) | AU2003255389A1 (es) |
| BR (1) | BR0313732A (es) |
| CA (1) | CA2494127A1 (es) |
| DE (1) | DE60319255T2 (es) |
| ES (1) | ES2300644T3 (es) |
| MX (1) | MXPA05001629A (es) |
| PA (1) | PA8580001A1 (es) |
| PL (1) | PL375588A1 (es) |
| RU (1) | RU2336275C2 (es) |
| TW (1) | TW200407326A (es) |
| UY (1) | UY27937A1 (es) |
| WO (1) | WO2004018472A2 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1984914A (zh) | 2004-08-31 | 2007-06-20 | 霍夫曼-拉罗奇有限公司 | 7－氨基－3－苯基－二氢嘧啶并[4,5－d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用 |
| CA2576818A1 (en) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 併用抗癌治療 |
| JP2012519281A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| CN102816162B (zh) * | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014089913A1 (zh) * | 2012-12-12 | 2014-06-19 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的并环化合物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9663524B2 (en) | 2013-03-15 | 2017-05-30 | Celgene Car Llc | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| CN104418860B (zh) * | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
| AU2015292818B2 (en) | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| US10457691B2 (en) | 2014-07-21 | 2019-10-29 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| US20170224700A1 (en) | 2014-08-08 | 2017-08-10 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA51229A (fr) | 2015-02-20 | 2021-03-24 | Incyte Corp | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| AU2017291812B2 (en) | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| EP3589284A4 (en) * | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| IL312465A (en) | 2018-05-04 | 2024-06-01 | Incyte Corp | FGFR inhibitor solid forms and processes for their preparation |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| SG11202106627WA (en) * | 2018-12-27 | 2021-07-29 | Les Laboratoires Servier Sas | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2949466A (en) | 1958-03-04 | 1960-08-16 | Parke Davis & Co | Pyrimidine compounds and means of producing the same |
| NL6704601A (es) | 1966-04-06 | 1967-10-09 | ||
| US4425346A (en) | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
| JPS60226882A (ja) | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
| WO1998024432A2 (en) | 1996-12-05 | 1998-06-11 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
| BR9911590A (pt) | 1998-05-26 | 2001-02-13 | Warner Lambert Co | Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular |
| TR200101102T2 (tr) | 1998-10-23 | 2002-01-21 | F.Hoffmann-La Roche Ag | Bisiklik nitrojen heterosikleler |
| CN1171889C (zh) | 1999-10-21 | 2004-10-20 | 霍夫曼-拉罗奇有限公司 | 作为p38蛋白激酶的抑制剂的杂烷基氨基－取代的双环氮杂环类化合物 |
| EP1226144B1 (en) | 1999-10-21 | 2006-12-27 | F. Hoffmann-La Roche Ag | Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| AR030053A1 (es) | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| JP4141830B2 (ja) | 2000-08-31 | 2008-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類 |
| PA8577501A1 (es) | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
-
2003
- 2003-07-21 US US10/623,972 patent/US7084270B2/en not_active Expired - Fee Related
- 2003-08-07 RU RU2005107314/04A patent/RU2336275C2/ru not_active IP Right Cessation
- 2003-08-07 CA CA002494127A patent/CA2494127A1/en not_active Abandoned
- 2003-08-07 BR BR0313732-5A patent/BR0313732A/pt not_active IP Right Cessation
- 2003-08-07 EP EP03792269A patent/EP1556384B1/en not_active Expired - Lifetime
- 2003-08-07 PL PL03375588A patent/PL375588A1/xx not_active Application Discontinuation
- 2003-08-07 WO PCT/EP2003/008744 patent/WO2004018472A2/en active IP Right Grant
- 2003-08-07 KR KR1020077017079A patent/KR20070087687A/ko not_active Application Discontinuation
- 2003-08-07 DE DE60319255T patent/DE60319255T2/de not_active Expired - Fee Related
- 2003-08-07 AU AU2003255389A patent/AU2003255389A1/en not_active Abandoned
- 2003-08-07 ES ES03792269T patent/ES2300644T3/es not_active Expired - Lifetime
- 2003-08-07 AT AT03792269T patent/ATE386743T1/de not_active IP Right Cessation
- 2003-08-07 CN CNB038191601A patent/CN1323080C/zh not_active Expired - Fee Related
- 2003-08-07 MX MXPA05001629A patent/MXPA05001629A/es active IP Right Grant
- 2003-08-07 JP JP2004530098A patent/JP2005538141A/ja active Pending
- 2003-08-11 PA PA20038580001A patent/PA8580001A1/es unknown
- 2003-08-12 UY UY27937A patent/UY27937A1/es not_active Application Discontinuation
- 2003-08-12 AR ARP030102914A patent/AR040971A1/es not_active Application Discontinuation
- 2003-08-13 TW TW092122274A patent/TW200407326A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1323080C (zh) | 2007-06-27 |
| ES2300644T3 (es) | 2008-06-16 |
| CN1675214A (zh) | 2005-09-28 |
| UY27937A1 (es) | 2004-02-27 |
| RU2336275C2 (ru) | 2008-10-20 |
| EP1556384B1 (en) | 2008-02-20 |
| KR20070087687A (ko) | 2007-08-28 |
| EP1556384A2 (en) | 2005-07-27 |
| AU2003255389A1 (en) | 2004-03-11 |
| WO2004018472A3 (en) | 2004-04-29 |
| MXPA05001629A (es) | 2005-04-25 |
| ATE386743T1 (de) | 2008-03-15 |
| US7084270B2 (en) | 2006-08-01 |
| PL375588A1 (en) | 2005-11-28 |
| WO2004018472A2 (en) | 2004-03-04 |
| TW200407326A (en) | 2004-05-16 |
| DE60319255D1 (de) | 2008-04-03 |
| US20040038995A1 (en) | 2004-02-26 |
| PA8580001A1 (es) | 2004-03-10 |
| CA2494127A1 (en) | 2004-03-04 |
| RU2005107314A (ru) | 2005-11-20 |
| BR0313732A (pt) | 2005-09-27 |
| DE60319255T2 (de) | 2009-03-05 |
| JP2005538141A (ja) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040971A1 (es) | Compuestos pirimido que tienen actividad antiproliferativa | |
| AR056785A1 (es) | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
| AR048640A1 (es) | Amidas del acido 4-amino- tieno(3,2-c) piridina-7-carboxilico | |
| AR041738A1 (es) | Compuestos derivados -3,4-dihidro-1h-pirimido[4,5-d]pirimidin-2-ona opticamente activos y su uso como agentes antitumorales. | |
| ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
| AR077485A2 (es) | Difenilureas substituidas con carboxiarilo como inhibidores de raf quinasa | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
| AR055554A1 (es) | Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos | |
| DE602006019221D1 (de) | Von dopamin-d3-rezeptoren | |
| ATE476431T1 (de) | Piperidin- und azetidinderivate als glyt1- inhibitoren | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| ECSP055958A (es) | 4-aminopirimidina-5-ona | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |